Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seasonal influenza vaccine with or without Advax adjuvant and Stratis needleless injector
ACTRN12612000709842Phase 2Completed
- Sponsor
- Vaxine
- Start
- Mar 2012
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of ARCT-2138 and ADVAX in influenza (4 arms), sponsored by Vaxine. Primary endpoint: Serum antibody titers. Started Mar 2012; status: completed.
02
Drugs
ARCT-2138ADVAX
03
Conditions
influenza
Beyond the preview
Go deeper on ACTRN12612000709842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000709842.